Rhythm and Blues Drugs and QT Prolongation

Similar documents
Prolonged QT Syndromes: Congenital and Acquired

Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD

Is There a Genomic Basis to Acquired Channelopathic disease

CONGENITAL LONG QT SYNDROME(CLQTS) ASSOCIATED WITH COMPLETE ATRIOVENTRICULAR BLOCK. A CASE REPORT.

Pearls of the ESC/ERS Guidelines 2015 Channelopathies

Genetics of Sudden Cardiac Death. Geoffrey Pitt Ion Channel Research Unit Duke University. Disclosures: Grant funding from Medtronic.

Long Q. Long QT Syndrome. A Guide for

Sudden cardiac death: Primary and secondary prevention

QT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency

TdP Mechanisms and CiPA

Genetic Testing for Cardiac Ion Channelopathies

SEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers !

Ionchannels and channelopaties in the heart. Viktória Szőts

Mechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS)

Long QT. Long QT Syndrome. A Guide for Patients

Pharmacogenomics of Drug-Induced Conditions

Case-Based Practical ECG Interpretation for the Generalist

Παναγιώτης Ιωαννίδης. Διευθυντής Τμήματος Αρρυθμιών & Επεμβατικής Ηλεκτροφυσιολογίας Βιοκλινικής Αθηνών

12/19/16. Disclosures

Genetic testing in Cardiomyopathies

Wojciech Szczepański, MD, PhD Department of Pediatrics, Endocrinology, Diabetology with Cardiology Division Medical University of Bialystok

Sudden Unexplained Death in Epilepsy (SUDEP) and Dravet Syndrome

Interpretation and Consequences of Repolarisation Changes in Athletes

Name of Presenter: Marwan Refaat, MD

Cardiovascular diseases

Antiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2017

Antiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification

Protocol. Genetic Testing for Cardiac Ion Channelopathies

Short QT Syndrome: Pharmacological Treatment

Management of Arrhythmia Syndromes in the Newborn and Very Young Child: Unique Risks & Barriers in this Age Population

The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes

Ionchannels and channelopaties in the heart

Genetic Testing for Congenital Long QT Syndrome

Drug induced QT prolongation and Torsades de Pointes (TdP) Mark Friesen, PharmD March 13, 2013

Acquired QT Prolongation and Clinical Implication. Ning Jiang, MD Cardiology Division, Brown University, USA

Description. Page: 1 of 31. Genetic Testing for Cardiac Ion Channelopathies. Last Review Status/Date: December 2015

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

2/1/2013. Poisoning pitfalls. The original pitfall

Acquired QT prolongation and Torsades de Pointes: a review and case report

Return to Titanic: Irregular Heart Beats. Ric Samson, MD Children s Heart Center - Nevada

Unexplained Sudden Cardiac Death in Saudi Arabia. Klinische Genetica

The most common. hospitalized patients. hypotension due to. filling time Rate control in ICU patients may be difficult as many drugs cause hypotension

Case studies in Channelopathies

Strength and weakness of genetic testing in clinical routine.

Volume 9, Number 14 September 2015

Preventing Sudden Death in Young Athletes. Outline. Scope of the Problem. Causes of SCD in Young Athletes. Sudden death in the young athlete

Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.

How to manage a patient with short QT syndrome?

FANS Long QT Syndrome Investigation Protocol (including suspected mutation carriers)

The Genetic Basis for Cardiac Dysrhythmias and the Long QT Syndrome

QUESTION: In a patient with different QT intervals, which one will give the highest prognostic accuracy? REPLY:

Antiarrhythmics & QT Prolongation: Avoiding Drug Interactions

Tailored therapy in long QT syndrome

Gene annotation for heart rhythm. 1. Control of heart rate 2. Action Potential 3. Ion channels and transporters 4. Arrhythmia 5.

LONG QT SYNDROME IN HAEMODIALYSIS PATIENT: A CASE REPORT

Nuplazid. (pimavanserin) New Product Slideshow

Cardiology Genetics Report Long QT Syndrome (LQTS) Panel

Arrhythmias (II) Ventricular Arrhythmias. Disclosures

PHARMACOLOGY OF ARRHYTHMIAS

QT Interval: The Proper Measurement Techniques.

WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY

Case Demonstrations in Congenital and Acquired Long QT Syndrome

Genetic Testing for Cardiac Ion Channelopathies. Description

Curriculum vitae Balázs Ördög

Antiarrhythmic Drugs

Asymptomatic Long QT. Prof. Dr. Martin Borggrefe Mannheim

Sudden cardiac death: focus on the genetics of channelopathies and cardiomyopathies

Long QT syndrome a genetic cardiac channelopathy

Update of Diagnosis and Management of Inherited Cardiac Arrhythmias

Antiarrhythmic Drugs Öner Süzer

ECG Changes in Patients Treated with Mild Hypothermia after Cardio-pulmonary Resuscitation for Out-of-hospital Cardiac Arrest

Stage I: Binning Dashboard

Patient Resources: Cardiac Channelopathies

Left cardiac sympathectomy to manage beta-blocker resistant LQT patients

FAMILIAR, CONGENITAL OR HEREDITARY SHORT QT SYNDROME: GUSSAK SYNDROME. UPDATE

Acquired conduction disturbance in structurally normal heart in children. Mi Young Han, M.D.,PhD. Kyung Hee University Hospital

3/17/2014. NCDR-14 ICD Registry WS # 24 Case Scenarios Including Syndromes w/ Risk of Sudden Death. Objectives

Genomics and Cardiac Arrhythmias

Ion channel dysfunction and diseases of the heart

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

Keeping Pace: The Genetics of Heritable Arrhythmia Syndromes

Atrial fibrillation in Cardiac Channelopathies

The long QT syndrome family of cardiac ion channelopathies: A HuGE review* Stephen M. Modell, MD, MS 1, and Michael H.

Dr.Binoy Skaria 13/07/15

Plotse hartdood & genetica

Further insights into inheritable arrhythmia syndromes: Focus on electrocardiograms Postema, P.G.

Congenital long QT syndrome of particularly malignant course connected with so far unknown mutation in the sodium channel SCN5A gene

ICD in a young patient with syncope

Molecular and genetic basis of sudden cardiac death

Amiodarone Prescribing and Monitoring: Back to the Future

Heterozygous mutation in the pore of potassium channel gene KvLQT1 causes an apparently normal phenotype in long QT syndrome

F T HERAPEUTICS. Risk Assessment for Antimicrobial Agent-Induced QTc Interval Prolongation and Torsades de Pointes. Robert C. Owens, Jr., Pharm.D.

Hereditary Conditions Predisposing to Sudden Death

When VF is the endpoint, wait and see is not always the best option.

PRESCRIBING ALERT

REVIEW ARTICLES Long QT syndrome and anaesthesia

a lecture series by SWESEMJR

Modeling of Anatomy, Electrophysiology and Tension Development in the Human Heart

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

Transcription:

Rhythm and Blues Drugs and QT Prolongation Dr Martin Quinn St Vincents University Hospital Irish Medication Safety Network conference Farmleigh 18 Oct 2013

Drugs and QT Prolongation Anti-psychotic, antidepressant, anti-histamine, antiarrhythmic and antibiotics are the commonest The risk of arrhythmia is increased x 3-8 fold Up to 3% of prescription are for medication with the potential to prolong the QT interval

QT prolongation with medication Na channel blockade

QT prolonging medications

Cardiac Ion Channels Action potential

Torsadede Pointes

Measuring QT interval-ecg Effected by heart rate and sex Normal for males <440ms Females <460 ms

Relationship of QT to heart rate

Congenital Long QT Syndrome 5-20% of patients with drug induced prolongation have previously unrecognized long QT Usually diagnosed in patients with aborted SCD or family member with SCD Examination normal, occasional deafness or skeletal and cardiac abnormalities

Long QT syndrome 100 of mutations in 10 genes have been identified Mutations in 3 genes encoding a cardiac ion channel account for the majority. Some have multiple mutations which increases the risk of SCD Syncope/SCD usually due to torsades de pointes Sometimes associated with bradycardias

Long QT syndrome Romano-Ward the autosomal dominant form Often variable penetrance Usually a disease of young and syncope and SCD rare in those over 40 years Post mortem usually normal Jervell-Lange-Neilsonautosomalrecessive with deafness

LQT-3 Na channel

Common forms of LQTS

Uncommon forms of LQTS Disease gene Functional effect Other features LQT4 ANK2 Altered intracellular calcium control and subcellular targeting of calcium control proteins Atrial fibrillation, sinus node dysfunction LQT5 KCNE1 Decreased IKs Similar to LQT1 LQT6 KCNE2 Decreased IKr LQT7 LQT8 KCNJ2 CACNA1C Decreased inward rectifier potassium current (IK1) Increased L-type calcium current No formal linkage in a family to date; isolated mutations in drugassociated QT prolongation Anderson-Tawil syndrome, including neurological symptoms and unusual facies Timothy syndrome: syndactyly, unusual facies, neurological defects LQT9 CAV3 Increased plateau INa Similar to LQT3 LQT10 SCN4B Increased plateau INa Similar to LQT3 AKAP9 SNTA1 Decreased IKs Increased plateau INa Preliminary report only Jervell-Lange- Nielsen KCNQ1 Congenital deafness,

Risk of long QT Most powerful predictor of risk is length of QTc The incidence of syncope or SCD over 10 years in 647 patients with LQT1-3 was <20% with QTc<446 and 70% with QTc>498

Factors to watch out for History of syncope Family history SCD Drowning SIDS Death while driving

Ray et al NEJM 2009 Anti-psycotics and QT prolongation Adjusted Incidence-Rate for Sudden Cardiac Death

Effect is dose related

Adjusted Rate of Sudden Cardiac Death among Current Users of Antipsychotic Drugs, According to Dose

QT prolongation with newer antipsychotics 478 events per 166,324 patient years of use (Ray et al 2009) or 2.9/1000 With higher doses the rate is 3.3/1000 3% of patients with schizophrenia (mean age 40 years) who were treated with risperidoneor quetiapine had prolongation of the QT interval The risk was doubled in older patients with dementia (6%)

QT Prolongation with Azithromycin HR for cardiovascular death 2.8 during 5 days of therapy 47 extra deaths per million prescriptions 1 for every 21,000 Increasing to 245 per million in patients with highest risk Ray et al 2012

Important drug interactions Isozyme QT prolonging drugs Inhibitor CYP3A4 Haloperidol Pimozide Erythromycin Clarithromycin Ketoconazole Itraconazole Diltiazem CYP1A2 Imipramine Ciprofloxacin CYP2D6 Thioridazine Imipramine Amitryptyline Fluoxetine Amiodarone

Prevention History Other medications Check pulse/bp ECG at baseline and within a few days of increase in dose

Conclusion QT prolongation with medications is common (3-6%) QT interval prolongation is dose related The risk of ventricular tachycardia/scd is related to the degree of prolongation of the QT interval With up to a 3 to 4 fold increase in the risk of SCD Drug interactions are particularly important in increasing the risk